Effect of T helper 1 (Th1)/Th2 cytokine on chemokine-induced dendritic cell functions

2006 ◽  
Vol 242 (2) ◽  
pp. 72-79 ◽  
Author(s):  
Jonathan M. Clingan ◽  
Yoshiki Yanagawa ◽  
Kazuya Iwabuchi ◽  
Kazunori Onoé
2019 ◽  
Vol 33 (2) ◽  
pp. 889-896 ◽  
Author(s):  
Sharon Witonsky ◽  
Virginia Buechner‐Maxwell ◽  
Amy Santonastasto ◽  
Robert Pleasant ◽  
Stephen Werre ◽  
...  

2009 ◽  
Vol 131 (2) ◽  
pp. 317-332 ◽  
Author(s):  
Rawleigh Howe ◽  
Stephanie Dillon ◽  
Lisa Rogers ◽  
Martin McCarter ◽  
Caleb Kelly ◽  
...  

Blood ◽  
2001 ◽  
Vol 97 (5) ◽  
pp. 1483-1490 ◽  
Author(s):  
Antonella Mencacci ◽  
Katia Perruccio ◽  
Angela Bacci ◽  
Elio Cenci ◽  
Roberta Benedetti ◽  
...  

Patients undergoing full haplotype-mismatched hematopoietic transplantations may experience severe intractable invasive fungal infections. To verify whether an imbalanced production of T-helper 1 (TH1) and TH2 cytokines may be responsible for susceptibility to fungal infections, C3H/HeJ (H-2k) recipient mice were lethally irradiated, received transplantations with T-cell–depleted allogeneic bone marrow (BM) cells from mice ofH-2d haplotype, and were infected withCandida albicans. At different time-points after transplantation, mice were assessed for pattern of TH cytokine production and susceptibility to infection. The results show that a long-term, donor-type chimerism was achieved as early as 2 weeks after BM transplantation (BMT), at the time when high-level production of TH2 cytokines (interleukin-4 [IL-4] and IL-10) and impaired production of TH1 cytokines (interferon-γ [IFN-γ] and IL-12] were observed. At this time, mice were highly susceptible to both disseminated and mucosal infections, as indicated by decreased survival, uncontrolled fungal growth, and failure to develop protective TH1 immunity. However, a predominant production of TH1 cytokines was observed by week 5 after BMT, at the time when mice developed donor-type protective TH1 responses and were resistant to infections. Therapeutic ablation of IL-4 or IL-10 greatly increased resistance to candidiasis. These results indicate that a dysregulated production of TH cytokines occurs in mice undergoing T-cell–depleted allogeneic BMT. The transient predominant production of TH2 cytokines over that of IL-12 impaired the ability of mice to develop antifungal TH1 resistance, an activity that could be efficiently restored upon treatment with TH2 cytokine antagonists.


2007 ◽  
Vol 55 (26) ◽  
pp. 11080-11086 ◽  
Author(s):  
Lisa Chuang ◽  
Keh-Gong Wu ◽  
Cindy Pai ◽  
Pei-Shan Hsieh ◽  
Jaw-Ji Tsai ◽  
...  

2015 ◽  
Vol 2015 ◽  
pp. 1-10 ◽  
Author(s):  
Jens Dannull ◽  
Chunrui Tan ◽  
Christine Farrell ◽  
Cynthia Wang ◽  
Scott Pruitt ◽  
...  

Background. Dendritic cell- (DC-) tumor fusion cells stimulate effectivein vivoantitumor responses. However, therapeutic approaches are dependent upon the coadministration of exogenous 3rd signals. The purpose of this study was to determine the mechanisms for inadequate 3rd signaling by electrofused DC-tumor cell hybrids.Methods. Murine melanoma cells were fused with DCs derived from C57BL/6 mice. Quantitative real-time PCR (qPCR) was used to determine relative changes in Th (T helper) 1 and Th2 cytokine gene expression. In addition, changes in gene expression of fusion cells were determined by microarray. Last, cytokine secretion by fusion cells upon inhibition of signaling pathways was analyzed by ELISA.Results. qPCR analyses revealed that fusion cells exhibited a downregulation of Th1 associated cytokines IL-12 and IL-15 and an upregulation of the Th2 cytokine IL-4. Microarray studies further showed that the expression of chemokines, costimulatory molecules, and matrix-metalloproteinases was deregulated in fusion cells. Lastly, inhibitor studies demonstrate that inhibition of the PI3K/Akt/mTOR signaling pathway could restore the secretion of bioactive IL-12p70 by fusion cells.Conclusion. Our results suggest that combining fusion cell-based vaccination with administration of inhibitors of the PI3K/Akt/mTOR signaling pathway may enhance antitumor responses in patients.


2008 ◽  
Vol 152 (3) ◽  
pp. 456-463 ◽  
Author(s):  
G. L. Theodorou ◽  
S. Marousi ◽  
J. Ellul ◽  
A. Mougiou ◽  
E. Theodori ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document